South San Francisco, CA
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
sonomabio.comThese are collections Sonoma Biotherapeutics is a part of. Click on the collection name to view similar companies.
Corporate Round
$30,000,000
Series B
$265,000,000
Series A
$30,000,000
Series A
$40,000,000
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Sonoma Biotherapeutics.